Tissue-targeted medicines, designed in vivo

Manifold Bio has built the first high-throughput in vivo (HTV) discovery engine—combining massively multiplexed in vivo screening and AI-powered design to create targeted biologics.

Learn More

the challenge

In vitro is not in vivo

Even the best AI models can only optimize for the context they are trained on. In vitro assays fail to recapitulate the complexity of living systems, missing key properties like PK and biodistribution.

the mdesign engine

Design, build, track, learn. All in-vivo.

We combine cutting-edge AI-guided protein design with the ability to directly test these designs in living systems.

Our engine sculpts pharmacokinetics, biodistribution, and other key properties of biologics directly in living systems, solving previously intractable challenges for tissue-specific delivery.

We have invented molecular tracking technologies that massively expand the scale of in vivo measurement of biologics. We don’t simulate biology, we have the wetware to measure it.

Novel wetware to enable HTV tracking

mCodes

Multiplexed protein barcodes decoded via NGS

mCodes is a new way of tracking proteins at scale. mCodes are inert peptide barcodes attached to each therapeutic molecule that are measured with high affinity detectors and DNA sequencing. This system allows us to quantify hundreds of candidate molecules—across tissues, in a single animal.

Single digit picomolar sensitivity
Catalog of over 1,000 mCodes to select from
Millions of protein-barcode combinations

AI-guided protein design

Generative Design

From DNA libraries to complete antibodies

Towards an in vivo world model

In the limit, we’re building a predictive model of living systems — one that integrates high-throughput in vivo data to map how biomolecules behave in the complexity of the body. This model empowers rational design of therapeutics by closing the loop between molecule, in vivo biology, and therapeutic outcome.

the opportunity

Targeted medicines spanning tissues and modalities.

Expanding the potential of tissue-targeted medicines across modalities and therapeutic areas through internal development and strategic partnerships.

mShuttle Portfolio

Growing a modular library of shuttles engineered and optimized in vivo to deliver payloads precisely, across any tissue, with high specificity and exposure.

In vivo shuttle profiles characterized with mCodes

Manifold shuttle portfolio with diverse profiles

Optimal shuttle therapeutics

the pipeline

Pipeline of potent biologics through tissue-specificity

Manifold's engine is enabling potent, tolerable new drug candidates through tissue-specificity. Starting with brain-specific delivery, and expanding to other tissues.